Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | PTPRB | P23467 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3004728 | 1.00 | MAPT (0.53) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL27103092 | 0.85 | KMT2A (0.62) | MAPTSMN1; SMN2MEN1KMT2AJAK2 | |
| SCHEMBL15709727 | 0.85 | LMNA (0.62) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL31323281 | 0.83 | RAB9A (0.59) | MAPTSMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL31323284 | 0.83 | RAB9A (0.59) | MAPTSMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL28746509 | 0.83 | HDAC8 (0.60) | PPARGPPARA | |
| SCHEMBL23964045 | 0.83 | KMT2A (0.52) | MAPTSMN1; SMN2MEN1KMT2APTPRB | |
| SCHEMBL18975494 | 0.83 | KMT2A (0.52) | MAPTSMN1; SMN2MEN1KMT2APTPRB | |
| SCHEMBL25932908 | 0.82 | KMT2A (0.51) | MAPTSMN1; SMN2MEN1KMT2AJAK2 | |
| SCHEMBL9270786 | 0.81 | MAPT (0.49) | MAPTLMNASMN1; SMN2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152664-B1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | MAPT 406/4885LMNA 1114/4885SMN1; SMN2 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.